[1]张蓉,俞立波,李连喜.组蛋白修饰与甲状腺癌[J].国际内分泌代谢杂志,2014,(05):348-350,359.[doi:10.3760/cma.j.issn.1673-4157.2014.05.017]
 Zhang Rong,Yu Libo,Li Lianxi..Histone modification and thyroid tumor[J].International Journal of Endocrinology and Metabolism,2014,(05):348-350,359.[doi:10.3760/cma.j.issn.1673-4157.2014.05.017]
点击复制

组蛋白修饰与甲状腺癌()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年05期
页码:
348-350,359
栏目:
综述
出版日期:
2014-10-31

文章信息/Info

Title:
Histone modification and thyroid tumor
作者:
张蓉俞立波李连喜
200233 上海交通大学附属第六人民医院内分泌代谢科; 上海市糖尿病研究所; 上海市糖尿病临床医学中心; 上海市糖尿病重点实验室(张蓉,俞立波,李连喜); 苏州大学医学部(张蓉)
Author(s):
Zhang Rong Yu Libo Li Lianxi.
Department of Endocrinology and Metabolism, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus,Shanghai 200233,China Correspondi
关键词:
组蛋白修饰 甲状腺癌 表观遗传学
Keywords:
Histone modification Thyroid tumor Epigenetics
DOI:
10.3760/cma.j.issn.1673-4157.2014.05.017
摘要:
组蛋白修饰是表观遗传学的重要组成部分,其在甲状腺癌的诊断、治疗等方面的研究越来越多。甲基化、乙酰化、磷酸化及泛素化组蛋白修饰均可参与甲状腺癌的发生。组蛋白修饰可参与调控甲状腺癌细胞的分化,影响肿瘤细胞的增殖。组蛋白去乙酰化酶抑制剂可用于甲状腺癌的治疗。
Abstract:
Histone modification is one of the major forms of epigenetic modifications, there are more and more researches on the applications of histone modifications in the diagnosis and treatment of thyroid tumor. Methylation, acetylation, phosphorylation and ubiquitin of histone modification involve in thyroid cancer. Histone modification can regulate the differentiation of thyroid cancer, influence the proliferation of tumor cells. Histone deacetylases may be used in the treatment of thyroid tumors.

参考文献/References:

[1] Kurdistani SK. Histone modifications in cancer biology and prognosis[M].Epigenetics and Disease. Springer Basel, 2011: 91-106.
[2] Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy[J].Cell, 2012,150(1):12-27.
[3] Russo D, Damante G, Puxeddu E, et al. Epigenetics of thyroid Cancer and novel therapeutic targets[J].J Mol Endocrinol, 2011,46(3):R73-R81.
[4] Weichert W, Roske A, Niesporek S, et al. Class Ⅰ histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class Ⅰ histone deacetylases in vitro and in vivo[J].Clin Cancer Res, 2008,14(6):1669-1677.
[5] Seligson DB, Horvath S, Mcbrian MA, et al. Global levels of histone modifications predict prognosis in different cancers[J].Am J Pathol, 2009,174(5):1619-1628.
[6] Mosashvilli D, Kahl P, Mertens C, et al. Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma[J].Cancer Sci, 2010,101(12):2664-2669.
[7] Puppin C, Passon N, Lavarone E, et al. Levels of histone acetylation in thyroid tumors[J].Biochem Biophys Res Commun, 2011,411(4):679-683.
[8] Poke FS, Qadi A, Holloway AF. Reversing aberrant methylation patterns in Cancer[J].Curr Med Chem, 2010,17(13):1246-1254.
[9] Kondo T, Nakazawa T, Ma D, et al. Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas[J].Lab Invest,2009,89(7):791-799.
[10] Lavarone E, Puppin C, Passon N, et al. The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid Cancer cell lines[J].Mol Cell Endocrinol, 2013,365(1):1-10.
[11] Moss TJ, Wallrath LL. Connections between epigenetic gene silencing and human disease[J].Mutat Res, 2007,618(1-2):163-174.
[12] Pérez-Cadahía B, Drobic B, Khan P, et al. Current understanding and importance of histone phosphorylation in regulating chromatin biology[J].Curr Opin Drug Discov Devel, 2010,13(5):613-622.
[13] Du HN. Transcription, DNA damage and beyond: the roles of histone ubiquitination and deubiquitination[J].Curr Protein Pept Sci, 2012,13(5):447-466.
[14] Mcginty RK, Kim J, Chatterjee C, et al. Chemically ubiquitylated histone H2B stimulates hDot1L-mediated intranucleosomal methylation[J].Nature, 2008,453(7196):812-816.
[15] Nakagawa T, Kajitani T, Togo S, et al. Deubiquitylation of histone H2A activates transcriptional initiation via trans-histone cross-talk with H3K4 di- and trimethylation[J].Genes Dev, 2008,22(1):37-49.
[16] Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets[J].Gastroenterology, 2004,127(5 Suppl 1):S51-S55.
[17] Agboola A, Musa AA, Ayoade BA, et al. Clinicopathological and molecular significance of Sumolyation marker(ubiquitin conjugating enzyme 9(UBC9))expression in breast Cancer of black women[J].Pathol Res Pract, 2014,210(1):10-17.
[18] Wang L, Banerjee S. Differential PIAS3 expression in human malignancy[J].Oncol Rep,2004,11(6):1319-1324.
[19] Hou P, Bojdani E, Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid Cancer cells by targeting major signaling pathways[J].J Clin Endocrinol Metab, 2010,95(2):820-828.
[20] 袁耿彪,匡安仁,范群,等. 维甲酸联合曲古抑素对甲状腺癌细胞的诱导分化作用[J].癌症, 2010,29(4):415-421.
[21] 包建东, 林秀峰, 俞惠新, 等. 曲古菌素 A 对甲状腺癌细胞 NIS 基因表达和摄碘功能的影响[J].中华核医学杂志, 2010(2): 116-119.
[22] Pugliese M, Fortunati N, Germano A, et al. Histone deacetylase inhibition affects Sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid Cancer cells[J].Thyroid, 2013,23(7):838-846.
[23] Catalano MG,Fortunati N,Pugliese M,et al. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid Cancer cells[J].J Clin Endocrinol Metab, 2012,97(7):E1150-E1159.
[24] Mitmaker EJ, Griff NJ, Grogan RH, et al. Modulation of matrix metalloproteinase activity in human thyroid Cancer cell lines using demethylating agents and histone deacetylase inhibitors[J].Surgery, 2011,149(4):504-511.
[25] 孙珂,刘纯. 苯丁酸钠对甲状腺滤泡癌细胞侵袭能力及MMP-9和TIMP-1表达的影响[J].中国肿瘤生物治疗杂志, 2009,16(1):67-70.
[26] Zuo H, Gandhi M, Edreira MM, et al. Downregulation of rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors[J].Cancer Res,2010,70(4):1389-1397.
[27] Altmann A, Eisenhut M, Bauder-Wüst U, et al. Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275[J].Eur J Nucl Med Mol Imaging,2010,37(12):2286-2297.
[28] Xiao X, Ning L, Chen H. Notch1 mediates growth suppression of papillary and follicular thyroid Cancer cells by histone deacetylase inhibitors[J].Mol Cancer Ther,2009,8(2):350-356.
[29] Adler JT, Hottinger DG, Kunnimalaiyaan M, et al. Inhibition of growth in medullary thyroid Cancer cells with histone deacetylase inhibitors and Lithium chloride[J].J Surg Res,2010,159(2):640-644.
[30] Ellis L, Atadja PW, Johnstone RW. Epigenetics in Cancer: targeting chromatin modifications[J].Mol Cancer Ther, 2009,8(6):1409-1420.

相似文献/References:

[1]叶婷婷,董艳.表观遗传学在子代代谢性疾病发生中的作用[J].国际内分泌代谢杂志,2014,(01):60.[doi:10.3760/cma.j.issn.1673-4157.2014.01.017]
 Ye Tingting,Dong Yan.Role of epigenetics in the development of metabolic diseases in offsprings[J].International Journal of Endocrinology and Metabolism,2014,(05):60.[doi:10.3760/cma.j.issn.1673-4157.2014.01.017]
[2]李兴佳,徐书杭,刘超.雌激素及其受体与甲状腺癌的关系[J].国际内分泌代谢杂志,2016,36(04):273.[doi:10.3760/cma.j.issn.1673-4157.2016.04.15]
 Li Xingjia,Xu Shuhang,Liu Chao.Relationship between estrogen, its receptors and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2016,36(05):273.[doi:10.3760/cma.j.issn.1673-4157.2016.04.15]
[3]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
 Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
[4]郑仁东,刘超.STAT3与甲状腺肿瘤[J].国际内分泌代谢杂志,2017,37(05):345.
 Zheng Rendong,Liu Chao..STAT3 and thyroid tumor[J].International Journal of Endocrinology and Metabolism,2017,37(05):345.
[5]孟祥慧 徐书杭 陈国芳 刘超.二甲双胍在甲状腺癌防治中的作用[J].国际内分泌代谢杂志,2018,38(04):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
 Meng Xianghui*,Xu Shuhang,Chen Guofang,et al.Role of metformin in prevention and treatment of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2018,38(05):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
[6]曹星月 武晓泓.基因拷贝数异常在甲状腺癌诊断和预后判断中的 应用进展[J].国际内分泌代谢杂志,2019,39(01):29.[doi:10.3760/cma.j.issn.1673-4157.2019.01.007]
 Cao Xingyue,Wu Xiaohong.Progress in the application of gene copy number variations in diagnosis and prognosis of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2019,39(05):29.[doi:10.3760/cma.j.issn.1673-4157.2019.01.007]
[7]张会峰 胡天赤 陈学勤 叶向荣 刘超.丙型肝炎病毒感染与自身免疫性甲状腺疾病 及甲状腺癌风险[J].国际内分泌代谢杂志,2019,39(02):128.[doi:10.3760/cma.j.issn.1673-4157.2019.02.014]
 Zhang Huifeng,Hu Tianchi,Chen Xueqin,et al.Relationship between hepatitis C virus infection and the risk of autoimmune thyroid diseases and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2019,39(05):128.[doi:10.3760/cma.j.issn.1673-4157.2019.02.014]
[8]张玉洁 孟召伟 章明放 宋丽丽 李宁.甲状腺疾病的代谢组学研究现状[J].国际内分泌代谢杂志,2019,39(03):173.[doi:10.3760/cma.j.issn.1673-4157.2019.03.007]
 Zhang Yujie,Meng Zhaowei,Zhang Mingfang,et al.Research status of metabolomics in thyroid diseases[J].International Journal of Endocrinology and Metabolism,2019,39(05):173.[doi:10.3760/cma.j.issn.1673-4157.2019.03.007]
[9]田勍,洪天配.甲状腺结节诊治过程中的难点与应对[J].国际内分泌代谢杂志,2021,41(06):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
 Tian Qing,Hong Tianpei..Difficulties and countermeasures in the diagnosis and treatment of thyroid nodules[J].International Journal of Endocrinology and Metabolism,2021,41(05):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
[10]张雅,相萍萍,徐书杭,等.经皮无水乙醇注射治疗甲状腺结节:老方法的新认识[J].国际内分泌代谢杂志,2022,42(06):469.[doi:10.3760/cma.j.cn121383-20210926-09075]
 Zhang Ya,Xiang Pingping,Xu Shuhang,et al.Percutaneous ethanol ablation for thyroid nodules: new perspectives on an old paradigm[J].International Journal of Endocrinology and Metabolism,2022,42(05):469.[doi:10.3760/cma.j.cn121383-20210926-09075]

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金资助项目(81170759) 通信作者:李连喜,Email:lilx@sjtu.edu.cn
更新日期/Last Update: 2014-09-20